![]()
|
|
||||||||
J Biol Chem, Vol. 273, Issue 29, 18443-18451, July 17, 1998
From the Insulin-like growth factor-2 (IGF-2) is expressed
in most embryonic tissues and is required for normal development during gestation. After birth IGF-2 expression is extinguished in most tissues, but the gene is often reactivated during tumorigenesis. Tumors
secrete high molecular weight forms of IGF-2 that result from aberrant
post-translational processing of pro-IGF-2. As a first step toward
understanding how high molecular weight IGF-2 peptides might contribute
to tumor progression, we have characterized the biosynthesis of IGF-2
in a human embryonic cell line. We have found that pro-IGF-2 can
initially form two disulfide isomers that undergo rearrangement to a
single conformation in vivo. The addition of
N-acetylgalactosamine to Ser71,
Thr72, Thr75, and Thr139 likely
occurs in the cis- Golgi apparatus. Sialic acid addition begins in the trans- Golgi apparatus, but IGF-2 peptides
must reach the trans-Golgi network for oligosaccharide
maturation to be completed. Endoproteolysis occurs concomitant to or
slightly after oligosaccharide maturation. Cleavage was observed only
at Arg104, resulting in the secretion of IGF-2-(1-104) and
free E-peptide. Proteolysis required basic residues in the P1
(Arg104) and P4 (Arg101) positions, was
completely blocked by a furin inhibitor, and was enhanced by
coexpression with furin, PACE4, PC6A, PC6B, and LPC. These data suggest
that members of the subtilisin-related proprotein convertase family
mediate processing of pro-IGF-2 at Arg104. We did not
detect the IGF-2 peptides that are most abundant in normal serum,
mature IGF-2, and IGF-2-(1-87), in this expression system, which
indicates that novel endoproteases are responsible for generating these
products.
Post-translational Processing of the Insulin-like Growth
Factor-2 Precursor
ANALYSIS OF O-GLYCOSYLATION AND ENDOPROTEOLYSIS
§,
,
, and
§
Howard Hughes Medical Institute and
§ Department of Biochemistry and Molecular Biology,
University of Chicago, Chicago, Illinois 60637
Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. W. B de Groot, B. Rikhof, J. van Doorn, H. J G Bilo, M. A Alleman, A. H Honkoop, and W. T A van der Graaf Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases Endocr. Relat. Cancer, December 1, 2007; 14(4): 979 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Qiu, J.-Y. Jiang, M. Bell, B. K. Tsang, and A. Gruslin Activation of Endoproteolytic Processing of Insulin-Like Growth Factor-II in Fetal, Early Postnatal, and Pregnant Rats and Persistence of Circulating Levels in Postnatal Life Endocrinology, October 1, 2007; 148(10): 4803 - 4811. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Wanderling, B. B. Simen, O. Ostrovsky, N. T. Ahmed, S. M. Vogen, T. Gidalevitz, and Y. Argon GRP94 Is Essential for Mesoderm Induction and Muscle Development Because It Regulates Insulin-like Growth Factor Secretion Mol. Biol. Cell, October 1, 2007; 18(10): 3764 - 3775. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. West, G. A. Neale, S. Pounds, B. C. Figueredo, C. Rodriguez Galindo, M. A. D. Pianovski, A. G. Oliveira Filho, D. Malkin, E. Lalli, R. Ribeiro, et al. Gene Expression Profiling of Childhood Adrenocortical Tumors Cancer Res., January 15, 2007; 67(2): 600 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kato, C. Jeanneau, M. A. Tarp, A. Benet-Pages, B. Lorenz-Depiereux, E. P. Bennett, U. Mandel, T. M. Strom, and H. Clausen Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis: SECRETION OF FIBROBLAST GROWTH FACTOR 23 REQUIRES O-GLYCOSYLATION J. Biol. Chem., July 7, 2006; 281(27): 18370 - 18377. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Remacle, A. V. Chekanov, V. S. Golubkov, A. Y. Savinov, D. V. Rozanov, and A. Y. Strongin O-Glycosylation Regulates Autolysis of Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) J. Biol. Chem., June 23, 2006; 281(25): 16897 - 16905. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Dissen, C. Garcia-Rudaz, V. Tapia, L. F. Parada, S.-Y. T. Hsu, and S. R. Ojeda Expression of the Insulin Receptor-Related Receptor Is Induced by the Preovulatory Surge of Luteinizing Hormone in Thecal-Interstitial Cells of the Rat Ovary Endocrinology, January 1, 2006; 147(1): 155 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Espelund, J. M. Bruun, B. Richelsen, A. Flyvbjerg, and J. Frystyk Pro- and mature IGF-II during diet-induced weight loss in obese subjects Eur. J. Endocrinol., December 1, 2005; 153(6): 861 - 869. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Qiu, A. Basak, M. Mbikay, B. K. Tsang, and A. Gruslin Role of pro-IGF-II processing by proprotein convertase 4 in human placental development PNAS, August 2, 2005; 102(31): 11047 - 11052. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Miraki-Moud, A. B. Grossman, M. Besser, J. P. Monson, and C. Camacho-Hubner A Rapid Method for Analyzing Serum Pro-Insulin-Like Growth Factor-II in Patients with Non-Islet Cell Tumor Hypoglycemia J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 3819 - 3823. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L. de Cicco, J. C. Watson, D. E. Bassi, S. Litwin, and A. J. Klein-Szanto Simultaneous Expression of Furin and Vascular Endothelial Growth Factor in Human Oral Tongue Squamous Cell Carcinoma Progression Clin. Cancer Res., July 1, 2004; 10(13): 4480 - 4488. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van Doorn, C. M. Hoogerbrugge, J. G. Koster, R. J. Bloemen, K. Hoekman, A. H. Mudde, and S. C. van Buul-Offers Antibodies Directed against the E Region of Pro-Insulin-like Growth Factor-II Used to Evaluate Non-Islet Cell Tumor-induced Hypoglycemia Clin. Chem., October 1, 2002; 48(10): 1739 - 1750. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Khatib, G. Siegfried, M. Chretien, P. Metrakos, and N. G. Seidah Proprotein Convertases in Tumor Progression and Malignancy : Novel Targets in Cancer Therapy Am. J. Pathol., June 1, 2002; 160(6): 1921 - 1935. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, R. L. De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells PNAS, August 17, 2001; (2001) 191199198. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Boulle, C. Gicquel, A. Logie, R. Christol, J.-J. Feige, and Y. Le Bouc Fibroblast Growth Factor-2 Inhibits the Maturation of Pro-Insulin-Like Growth Factor-II (Pro-IGF-II) and the Expression of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in the Human Adrenocortical Tumor Cell Line NCI-H295R Endocrinology, September 1, 2000; 141(9): 3127 - 3136. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-M. Khatib, G. Siegfried, A. Prat, J. Luis, M. Chretien, P. Metrakos, and N. G. Seidah Inhibition of Proprotein Convertases Is Associated with Loss of Growth and Tumorigenicity of HT-29 Human Colon Carcinoma Cells. IMPORTANCE OF INSULIN-LIKE GROWTH FACTOR-1 (IGF-1) RECEPTOR PROCESSING IN IGF-1-MEDIATED FUNCTIONS J. Biol. Chem., August 10, 2001; 276(33): 30686 - 30693. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Bassi, R. Lopez De Cicco, H. Mahloogi, S. Zucker, G. Thomas, and A. J. P. Klein-Szanto Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells PNAS, August 28, 2001; 98(18): 10326 - 10331. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |